You are here: Home » 0 » » Archives for 0st

Unveiling the 8th Future Investment Initiative’s theme: “Infinite Horizons: Investing Today, Shaping Tomorrow”

RIYADH, Saudi Arabia, April 18, 2024 (GLOBE NEWSWIRE) — The Future Investment Initiative (FII) Institute is excited to announce the theme for its upcoming 8th edition of the FII conference, scheduled for October 29–31, 2024, at the prestigious King Abdulaziz International Conference Centre (KAICC) in Riyadh, Saudi Arabia.

Under the captivating theme ‘Infinite Horizons: investing today, shaping tomorrow’, FII8 will ignite discussions on how investment can serve as a catalyst for a prosperous and sustainable future, pushing the boundaries of what is possible for humanity.

FII8 promises to be a melting pot of innovative ideas, bringing together global leaders, entrepreneurs, political leaders, media and decision–makers in finance, AI, sustainability, energy, geoeconomics, space and beyond. By focusing on the theme of ‘Infinite Horizons’, this year’s conference will challenge attendees to think beyond conventional limits and explore investment opportunities that can bridge current challenges with future possibilities.

Richard Attias, CEO and board member of FII Institute, emphasized the significance of the theme, stating that “Infinite Horizons is not just a theme; it's a clarion call to expand our collective vision and embrace the limitless prospects of the future. It embodies our commitment to driving conversations that lead to a future where investment knows no bounds and works towards a better tomorrow for all.”

FII8, organized by the FII Institute, founded by PIF, will adopt an innovative format as an exclusive week for FII Institute members, invited delegates, and strategic partners. Discussions at the conference will be data–driven, ensuring that insights are grounded in facts and actionable strategies.

For media inquiries, please contact:

Phone: +966 53 978 2030

Email: Media@fii–institute.org

The Future Investment Initiative (FII) Institute is a global non–profit foundation dedicated to making an impact on humanity. Through our investment arm, we champion innovation in Artificial Intelligence (AI) & Robotics, Education, Healthcare, and Sustainability, transforming ideas into real–world solutions.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fc52762c–6e57–4254–a6df–7f3b4af1c61b


GLOBENEWSWIRE (Distribution ID 1000935387)

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects. 

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) — The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before the cells become cancerous and spread to other parts of the body is crucial. For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy. Although effective, these treatments come with significant side effects, such as redness, blistering, and peeling, with recovery times that can be lengthy and uncomfortable. The global actinic keratosis treatment market size is projected to reach as high as $10 billion USD by 2031, fuelled by increasing cases of AK and rising healthcare spending.

Derm–Biome Pharmaceuticals is a Vancouver–based biopharmaceutical company that has developed a topical anticancer treatment for patients with or at high risk of developing multiple AKs. In a recent UV–induced skin cancer trial, mice were exposed to UVB radiation over a period of 25 weeks. The prolonged exposure mimics chronic sun exposure over time and replicates the gradual progression from precancerous skin conditions to cutaneous squamous cell carcinoma (cSCC). Topical application of Derm–Biome’s compound prior to UVB exposure significantly reduced the number and size of precancer lesions, while treatment blocked the progression of squamous cell carcinoma tumors.

Frédéric Couture, Researcher and Head of Pharmaceutical Sciences at TransBIOtech: “My research group conducted this study using Derm–Biome’s compound. The compound exhibited a significant protective effect without toxicity or side effects. Moreover, existing tumor progression was blocked with drug treatment. We actually noticed an improvement to the look of skin treated with the compound.”

Dr. Poul Sorensen, University of British Columbia Professor and Distinguished Scientist at BC Cancer Research Centre, and Derm–Biome CSO: “The results of these studies are very promising. We tested our compound using a very aggressive UV–induced skin cancer model. We observed highly significant decreases in the number of tumors in treated mice and strong preventative effects when mice were pretreated with the compound. These findings suggest that our compound has great potential to be a highly effective and well–tolerated agent for both the treatment and prevention of squamous cell carcinoma.”

Derm–Biome CEO Gordon Eberwein: “Currently available topical treatments cause debilitating side effects that make them unattractive to patients. There is a real need for safer and more targeted topical therapies.”

Derm–Biome expects to start topical formulation development this summer, with IND–enabling studies slated to begin in Q4.

About Derm–Biome Pharmaceuticals, Inc.
Derm–Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to improving skin health. We are developing novel topical therapies for inflammatory skin diseases and precancer/non–melanoma skin cancers that are both highly effective and well tolerated by skin.

Derm–Biome is about to kick off a $3M USD seed funding round. For investor inquiries please contact:

Gordon Eberwein
geberwein@derm–biome.com
https://derm–biomepharmaceuticals.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/54b222f0–2c93–417d–8bba–33853a2dd94a

 


GLOBENEWSWIRE (Distribution ID 9091271)